[1] 周宏灏.遗传药理学 [M].科学出版社, 2001.
[2] Garrod AE.The incidence of alkaptonuria:a study in chemical individuality.1902 [classical article] [J].Yale J BiolMed, 2002, 75(4):221-231.
[3] Garrod AE.The inborn errors of metabolism [M].London, UK:Oxford Univ Press, 1909.
[4] Bateson W.Mendel's principles of heredity:A defence [M].Cambridge, UK:Cambridge Univ.Press, 1902.
[5] Garrod AE.The inborn factors of disease [M].London, UK:Oxford Univ Press, 1931.
[6] Fox AL.The relationship between chemical constitution and taste [J].Proc Natl Acad Sci USA, 1932, 18(1):115-120.
[7] Snyder LH.Studies in human inheritance IX.The inheritance of taste deficiency in man [J].Ohio J Sci, 1932, 32: 436-468.
[8] Clayman C, B Arnold J, Hockwald RS, et al. Toxicity of primaquine in Caucasians [J].J Am Med Assoc, 1952, 149(17):1563-1568.
[9] ALVING AS, CARSON PE, FLANAGAN CL, et al. Enzymatic deficiency in primaquine-sensitive erythrocytes [J]. Science, 1956, 124(3220):484-485.
[10] Luzatto L, Mehta A, Vulliamy MY.The metabolic and molecular basis of inherited diseases [M].New York, USA:McGraw-Hill Inc., 2001:4517-4553.
[11] Lehmann H, Ryan E.The familial incidence of low pseudocholinesterase level [J].Lancet, 1956, 271(6934), 124.
[12] Kalow W, Staron N.On distribution and inheritance of atypical forms of human serum cholinesterase, as indicated by dibucaine numbers [J].Can J Med Sci, 1957, 35(12): 1305-1320.
[13] Evans DA, Manley FA, McKusick VA.Genetic control of isoniazid metabolism in man [J].Br Med J, 1960, 2 (5197):485-491.
[14] Blum M, Demierre A, Grant DM, et al. Molecular mechanism of slow acetylation in man [J].Proc Natl Acad Sci USA, 1991, 88(12):5237-5241.
[15] Vatsis KP, Martel KJ, Weber WW.Diverse point mutations in the human gene for polymorphic N-acetyltrans-ferase [J].Proc Natl Acad Sci USA, 1991, 88(14):6333-6337.
[16] Bönicke R, Reif W.Enzymatische Inaktivierung von Isonicotins& #xE4; ure hydrazide im menschlichen und tierischen Organismus [J].Arch Exp Pathol Pharmakol, 1953, 220 (4):321-333.
[17] Vogel F.Moderne Probleme der Humangenetik.Ergebn Inn Med Kinderheilkd [J].1959, 12(52):125.
[18] Kalow W.Pharmacogenetics:heredity and the response to drugs [M].USA:Saunders WB& Philadelphia Co, 1962.
[19] Zhou HH, Koshakji RP, Silberstein DJ, et al. Racial differences in drug response:Altered sensitivity to and clearance of propranolol in men of Chinese descent as compared with American whites [J].N Eng J Med, 1989, 320(9): 565-570.
[20] Morton NE.Into the post-Hap Map era [J].Adv Genet, 2008, 60:727-742.
[21] Rosenberg W, Donald A.Evidence based medicine:an approach to clinical problem-solving [J].BMJ, 1995, 310 (6987):1122-1126.
[22] Giacomini KM, Brett CM, Altman RB, et al. The pharmacogenetics research network:from SNP discovery to clinical drug response [J].Clin Pharmacol Ther, 2007, 81 (3):328-345.
[23] Thorn CF, Klein TE, Altman RB.PharmGKB:the pharmacogenetics and pharmacogenomics knowledge base [J]. MethodsMol Biol, 2005, 311:179-191.
[24] Arrell DK, Niederl? nder NJ, Perez-Terzic C, et al. Pharmacoproteomics: advancing the efficacy and safety of regenerative therapeutics [J].Clin Pharmacol Ther, 2007, 82(3):316-319. |
